Thiogenesis Therapeutics Corp (TTIPF)

$0.00 -2.58 (-99.94%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 500
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 0%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada.

Industry: Biotechnology
Sector: Healthcare
Phone: 888-223-9165
Address:
4 King Street West, Suite 401, Toronto, Canada
wavess
wavess Jul. 15 at 4:50 PM
$TTIPF New company breakdown for Thiogenesis Therapeutics: https://x.com/StckMasterFlash/status/1944873428017611032 Advancing a next-generation cysteamine platform with broad potential across mitochondrial and oxidative stress-driven disorders, TTI has three active Phase 2 programs, including MELAS, Leigh Syndrome, and pediatric MASH, positioning the company for multiple near-term catalysts in high-need, billion-dollar orphan markets.
0 · Reply
wavess
wavess Jul. 14 at 9:03 PM
$TTIPF Advancing best-in-class mitochondrial therapeutics with near-term human efficacy readouts, Thiogenesis Therapeutics is clinical-stage biotech company focused on developing cysteamine-based therapeutics targeting pediatric and orphan diseases rooted in mitochondrial dysfunction and oxidative stress: https://www.reddit.com/r/Canadapennystocks/comments/1lrv9s9/significant_clinical_progress_for_thiogenesis/ TTI's lead asset being developed for three Phase 2 indications, each with multi-billion dollar addressable markets and no approved therapies, including MELAS, Leigh Syndrome Spectrum (LSS) and Pediatric MASH. Corporate Presentation: https://cdn.prod.website-files.com/6324f3c1cd40a857e0ea27a4/685eda4d93c31efab5e329eb_TTI%20Corp%20-%20Presentation%20%20070125%20.pdf
0 · Reply
wavess
wavess Jul. 11 at 7:57 PM
$TTIPF Running in parallel with Phase 2 trials for MELAS and MASH, Thiogenesis Therapeutics (TTI.v TTIPF) is additionally advancing a Phase 2a trial for Leigh Syndrome—a devastating pediatric mitochondrial disorder with no approved treatments. This trial represents a major step toward validating TTI’s core platform in high-value, orphan drug markets. With dosing now underway and interim data from MELAS trials expected soon, TTI is approaching a critical inflection point that could redefine its clinical and commercial trajectory. Dive into the full clinical roadmap here: https://www.reddit.com/r/Canadapennystocks/comments/1lrv9s9/significant_clinical_progress_for_thiogenesis/ Posted on Behalf of Thiogenesis Therapeutics Corp.
0 · Reply
wavess
wavess Jul. 10 at 7:49 PM
$TTIPF Running alongside two other trials, Thiogenesis Therapeutics is advancing its European Phase 2 trial for MELAS—a rare, currently untreatable mitochondrial disease. With dosing underway in the Netherlands and France, and a 3-month interim efficacy readout expected in the near term, TTI is positioning itself for a major value inflection point in a high-need, orphan drug market. For more info on TTI and its two other current trials, refer to this breakdown: https://www.reddit.com/r/Canadapennystocks/comments/1lrv9s9/significant_clinical_progress_for_thiogenesis/
0 · Reply
wavess
wavess Jul. 7 at 7:24 PM
$TTIPF Triple Trial Momentum: Thiogenesis Therapeutics (TTI.v TTIPF) Surges on Breakthroughs in Mitochondrial & Metabolic Disease Pipeline Targeting rare, high-need diseases like MELAS, Leigh Syndrome (in partnership with CHOP), and MASH, Thiogenesis Therapeutics (TTI.v TTIPF) is gaining serious traction as its lead candidate, TTI-0102, advances through three Phase 2 trials. Backed by EMA guidance and growing regulatory momentum, TTI is emerging as a key player in pediatric and metabolic drug development. Check out the full story here: https://www.reddit.com/r/Canadapennystocks/comments/1lrv9s9/significant_clinical_progress_for_thiogenesis/
0 · Reply
wavess
wavess Jul. 4 at 9:50 PM
$TTIPF Today, Thiogenesis Therapeutics is up over 12% over 6x the average volume amid three active clinical trials for its lead candidate, TTI-0102, a prodrug designed to target mitochondrial and oxidative stress-related disorders. Check out a breakdown of TTI's current clinical pipeline here: https://x.com/StckMasterFlash/status/1937578501932192183
0 · Reply
wavess
wavess Jul. 3 at 10:07 PM
$TTIPF As the FDA faces mounting delays, Thiogenesis Therapeutics is quietly making clinical strides in Europe—recently dosing its first patient in France and expanding its Phase 2 trial for MELAS, a rare and debilitating mitochondrial disease with no approved treatments: https://x.com/StckMasterFlash/status/1935049659816214802 With interim results expected this fall, and a novel sulfur-based therapy targeting the root causes of mitochondrial dysfunction, TTI is emerging as a biotech to watch in the high-need orphan disease space, with two other active trials currently running.
0 · Reply
wavess
wavess Jul. 2 at 5:10 PM
$TTIPF Recently, Thiogenesis Therapeutics received FDA clearance to initiate a Phase 2a clinical trial for its lead candidate, TTI-0102, in patients with Leigh Syndrome Spectrum (LSS)—a rare, life-threatening mitochondrial disease with no approved therapies. Notably, the trial will be led by the Children’s Hospital of Philadelphia (CHOP), a world leader in pediatric mitochondrial research, underscoring the scientific credibility and clinical importance of this program. The two-stage trial will assess safety, pharmacokinetics, and early efficacy of TTI-0102 in both adolescent and pediatric LSS patients, with the CHOP team—led by Drs. Zarazuela Zolkipli-Cunningham and Marni Falk—highlighting its potential to deliver meaningful clinical benefit. Full News Breakdown: https://x.com/StckMasterFlash/status/1932861013423984766 Posted on Behalf of Thiogenesis Therapeutics Corp.
0 · Reply
wavess
wavess Jun. 30 at 8:16 PM
$TTIPF Advancing a rare disease pipeline, Thiogenesis Therapeutics has three active clinical trials targeting mitochondrial and oxidative stress-related disorders: 1) Phase 2a Trial in Leigh Syndrome Spectrum (LSS) – Now enrolling in collaboration with the Children’s Hospital of Philadelphia (CHOP), a global leader in pediatric mitochondrial care. 2) Phase 2 Trial in For MELAS – Running in Europe targeting a devastating mitochondrial disease with no approved treatments in the U.S. or EU. 3) Phase 2a Trial in MASH – Running with supportive scientific advice from the EMA and targeting highly underserved metabolic liver disease. With growing clinical momentum and a unique sulfur-based platform, TTI is positioned at the forefront of mitochondrial medicine. Latest News Breakdown: https://x.com/StckMasterFlash/status/1937894383744934106 Posted on Behalf of Thiogenesis Therapeutics Corp.
0 · Reply
wavess
wavess Jun. 26 at 4:30 PM
$TTIPF Yesterday, Thiogenesis Therapeutics announced it has secured a major regulatory milestone in Europe—receiving supportive scientific advice from the EMA to initiate a Phase 2a trial of TTI-0102 in children with MASH, a serious and underserved metabolic liver disease. This marks the third active Phase 2 program for TTI-0102, adding to ongoing trials for MELAS in Europe and Leigh syndrome in the U.S., and further solidifies the company’s IP and regulatory footing with new EU patent protection through 2038. With multiple rare disease indications now advancing in parallel, TTI is rapidly positioning itself as a clinical-stage leader in pediatric mitochondrial and metabolic therapeutics. Check out the full story here: https://x.com/StckMasterFlash/status/1937894383744934106 Posted on Behalf of Thiogenesis Therapeutics Corp.
0 · Reply
Latest News on TTIPF
No data available.
wavess
wavess Jul. 15 at 4:50 PM
$TTIPF New company breakdown for Thiogenesis Therapeutics: https://x.com/StckMasterFlash/status/1944873428017611032 Advancing a next-generation cysteamine platform with broad potential across mitochondrial and oxidative stress-driven disorders, TTI has three active Phase 2 programs, including MELAS, Leigh Syndrome, and pediatric MASH, positioning the company for multiple near-term catalysts in high-need, billion-dollar orphan markets.
0 · Reply
wavess
wavess Jul. 14 at 9:03 PM
$TTIPF Advancing best-in-class mitochondrial therapeutics with near-term human efficacy readouts, Thiogenesis Therapeutics is clinical-stage biotech company focused on developing cysteamine-based therapeutics targeting pediatric and orphan diseases rooted in mitochondrial dysfunction and oxidative stress: https://www.reddit.com/r/Canadapennystocks/comments/1lrv9s9/significant_clinical_progress_for_thiogenesis/ TTI's lead asset being developed for three Phase 2 indications, each with multi-billion dollar addressable markets and no approved therapies, including MELAS, Leigh Syndrome Spectrum (LSS) and Pediatric MASH. Corporate Presentation: https://cdn.prod.website-files.com/6324f3c1cd40a857e0ea27a4/685eda4d93c31efab5e329eb_TTI%20Corp%20-%20Presentation%20%20070125%20.pdf
0 · Reply
wavess
wavess Jul. 11 at 7:57 PM
$TTIPF Running in parallel with Phase 2 trials for MELAS and MASH, Thiogenesis Therapeutics (TTI.v TTIPF) is additionally advancing a Phase 2a trial for Leigh Syndrome—a devastating pediatric mitochondrial disorder with no approved treatments. This trial represents a major step toward validating TTI’s core platform in high-value, orphan drug markets. With dosing now underway and interim data from MELAS trials expected soon, TTI is approaching a critical inflection point that could redefine its clinical and commercial trajectory. Dive into the full clinical roadmap here: https://www.reddit.com/r/Canadapennystocks/comments/1lrv9s9/significant_clinical_progress_for_thiogenesis/ Posted on Behalf of Thiogenesis Therapeutics Corp.
0 · Reply
wavess
wavess Jul. 10 at 7:49 PM
$TTIPF Running alongside two other trials, Thiogenesis Therapeutics is advancing its European Phase 2 trial for MELAS—a rare, currently untreatable mitochondrial disease. With dosing underway in the Netherlands and France, and a 3-month interim efficacy readout expected in the near term, TTI is positioning itself for a major value inflection point in a high-need, orphan drug market. For more info on TTI and its two other current trials, refer to this breakdown: https://www.reddit.com/r/Canadapennystocks/comments/1lrv9s9/significant_clinical_progress_for_thiogenesis/
0 · Reply
wavess
wavess Jul. 7 at 7:24 PM
$TTIPF Triple Trial Momentum: Thiogenesis Therapeutics (TTI.v TTIPF) Surges on Breakthroughs in Mitochondrial & Metabolic Disease Pipeline Targeting rare, high-need diseases like MELAS, Leigh Syndrome (in partnership with CHOP), and MASH, Thiogenesis Therapeutics (TTI.v TTIPF) is gaining serious traction as its lead candidate, TTI-0102, advances through three Phase 2 trials. Backed by EMA guidance and growing regulatory momentum, TTI is emerging as a key player in pediatric and metabolic drug development. Check out the full story here: https://www.reddit.com/r/Canadapennystocks/comments/1lrv9s9/significant_clinical_progress_for_thiogenesis/
0 · Reply
wavess
wavess Jul. 4 at 9:50 PM
$TTIPF Today, Thiogenesis Therapeutics is up over 12% over 6x the average volume amid three active clinical trials for its lead candidate, TTI-0102, a prodrug designed to target mitochondrial and oxidative stress-related disorders. Check out a breakdown of TTI's current clinical pipeline here: https://x.com/StckMasterFlash/status/1937578501932192183
0 · Reply
wavess
wavess Jul. 3 at 10:07 PM
$TTIPF As the FDA faces mounting delays, Thiogenesis Therapeutics is quietly making clinical strides in Europe—recently dosing its first patient in France and expanding its Phase 2 trial for MELAS, a rare and debilitating mitochondrial disease with no approved treatments: https://x.com/StckMasterFlash/status/1935049659816214802 With interim results expected this fall, and a novel sulfur-based therapy targeting the root causes of mitochondrial dysfunction, TTI is emerging as a biotech to watch in the high-need orphan disease space, with two other active trials currently running.
0 · Reply
wavess
wavess Jul. 2 at 5:10 PM
$TTIPF Recently, Thiogenesis Therapeutics received FDA clearance to initiate a Phase 2a clinical trial for its lead candidate, TTI-0102, in patients with Leigh Syndrome Spectrum (LSS)—a rare, life-threatening mitochondrial disease with no approved therapies. Notably, the trial will be led by the Children’s Hospital of Philadelphia (CHOP), a world leader in pediatric mitochondrial research, underscoring the scientific credibility and clinical importance of this program. The two-stage trial will assess safety, pharmacokinetics, and early efficacy of TTI-0102 in both adolescent and pediatric LSS patients, with the CHOP team—led by Drs. Zarazuela Zolkipli-Cunningham and Marni Falk—highlighting its potential to deliver meaningful clinical benefit. Full News Breakdown: https://x.com/StckMasterFlash/status/1932861013423984766 Posted on Behalf of Thiogenesis Therapeutics Corp.
0 · Reply
wavess
wavess Jun. 30 at 8:16 PM
$TTIPF Advancing a rare disease pipeline, Thiogenesis Therapeutics has three active clinical trials targeting mitochondrial and oxidative stress-related disorders: 1) Phase 2a Trial in Leigh Syndrome Spectrum (LSS) – Now enrolling in collaboration with the Children’s Hospital of Philadelphia (CHOP), a global leader in pediatric mitochondrial care. 2) Phase 2 Trial in For MELAS – Running in Europe targeting a devastating mitochondrial disease with no approved treatments in the U.S. or EU. 3) Phase 2a Trial in MASH – Running with supportive scientific advice from the EMA and targeting highly underserved metabolic liver disease. With growing clinical momentum and a unique sulfur-based platform, TTI is positioned at the forefront of mitochondrial medicine. Latest News Breakdown: https://x.com/StckMasterFlash/status/1937894383744934106 Posted on Behalf of Thiogenesis Therapeutics Corp.
0 · Reply
wavess
wavess Jun. 26 at 4:30 PM
$TTIPF Yesterday, Thiogenesis Therapeutics announced it has secured a major regulatory milestone in Europe—receiving supportive scientific advice from the EMA to initiate a Phase 2a trial of TTI-0102 in children with MASH, a serious and underserved metabolic liver disease. This marks the third active Phase 2 program for TTI-0102, adding to ongoing trials for MELAS in Europe and Leigh syndrome in the U.S., and further solidifies the company’s IP and regulatory footing with new EU patent protection through 2038. With multiple rare disease indications now advancing in parallel, TTI is rapidly positioning itself as a clinical-stage leader in pediatric mitochondrial and metabolic therapeutics. Check out the full story here: https://x.com/StckMasterFlash/status/1937894383744934106 Posted on Behalf of Thiogenesis Therapeutics Corp.
0 · Reply
wavess
wavess Jun. 25 at 3:11 PM
$TTIPF Today, Thiogenesis Therapeutics announced that the European Medicines Agency (EMA) has provided supportive scientific advice for Thiogenesis’ Investigational Medicinal Product Dossier (IMPD), enabling a Phase 2a clinical trial of TTI‑0102 in pediatric patients with metabolic dysfunction-associated steatohepatitis (MASH): [NEWS RELEASE] This development advances TTI-0102 as a promising therapeutic candidate across multiple pediatric mitochondrial and metabolic diseases and strengthens TTI's IP and regulatory position in Europe amid its ongoing Phase 2 trials in Europe for MELAS as well as its IND-cleared Phase 2a trial for Leigh syndrome (LSS) in the U.S. More info on TTI's other trials: https://x.com/StckMasterFlash/status/1937578501932192183
0 · Reply
newsfile_corp
newsfile_corp Jun. 25 at 1:01 PM
https://nfne.ws/256736 $TTIPF $TTI.TSXV #InvestmentBanking #Patent #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Investing
0 · Reply
wavess
wavess Jun. 24 at 6:24 PM
$TTIPF June has marked a busy month for Thiogenesis Therapeutics, advancing its position as a leader in mitochondrial medicine with major clinical momentum this month across both sides of the Atlantic. TTI initiated a Phase 2a trial for Leigh Syndrome Spectrum in collaboration with the Children’s Hospital of Philadelphia (CHOP)—one of the world’s foremost centers in pediatric mitochondrial disorders: https://x.com/StckMasterFlash/status/1932861013423984766 Simultaneously, TTI is actively dosing patients in its Phase 2 trial for MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes) at clinical sites across Europe: https://x.com/StckMasterFlash/status/1922740812284055630
0 · Reply
wavess
wavess Jun. 23 at 6:33 PM
$TTIPF Held in collaboration with the Children’s Hospital of Philadelphia (CHOP), a global leader in pediatric mitochondrial care, Thiogenesis Therapeutics is advancing its lead candidate, TTI-0102, into a Phase 2a trial for Leigh Syndrome Spectrum (LSS). Notably, this is a landmark collaboration underscores the scientific strength behind TTI’s approach and marks a major step toward addressing a critical unmet medical need, as LSS is a devastating mitochondrial disorder with no approved therapies. Check out the full story here: https://x.com/StckMasterFlash/status/1932861013423984766
0 · Reply
wavess
wavess Jun. 20 at 7:35 PM
$TTIPF Thiogenesis Therapeutics has received FDA clearance to begin a Phase 2a trial of its lead candidate, TTI-0102, for the treatment of Leigh Syndrome Spectrum (LSS)—a rare, life-threatening mitochondrial disorder with no approved therapies: https://x.com/StckMasterFlash/status/1932861013423984766 Reflecting both the scientific credibility of Thiogenesis’ approach and the strong preclinical rationale for targeting oxidative stress in LSS patients, the trial will be held in collaboration with the Children’s Hospital of Philadelphia (CHOP), a globally recognized leader in pediatric mitochondrial medicine.
0 · Reply
newsfile_corp
newsfile_corp Jun. 20 at 1:01 PM
https://nfne.ws/256143 $TTIPF $TTI.TSXV #InvestmentBanking #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Investing
0 · Reply
wavess
wavess Jun. 19 at 6:18 PM
$TTIPF As U.S. clinical trials face growing delays, Thiogenesis Therapeutics is leveraging the EU’s more efficient framework to accelerate enrollment and generate early efficacy data, having activated its second clinical site in France for its ongoing Phase 2 trial of TTI-0102 in MELAS patients—highlighting the strategic advantage of conducting rare disease trials in Europe: https://x.com/StckMasterFlash/status/1935049659816214802 With streamlined regulatory pathways, faster site activation, and greater scientific collaboration, Europe is proving to be an increasingly attractive jurisdiction for clinical-stage biotech companies. Now with multiple active sites across France and the Netherlands, and interim results expected in September 2025, TTI is gaining momentum in a market known for supporting high-unmet-need orphan drug development. Posted on Behalf of Thiogenesis Therapeutics Corp.
0 · Reply
wavess
wavess Jun. 18 at 6:29 PM
$TTIPF Yesterday, Thiogenesis Therapeutics (TTI.v TTIPF) announced it has activated its second clinical site in France for the Phase 2 trial of TTI-0102, a next-gen thiol-based therapy for MELAS—a rare and devastating mitochondrial disease: https://x.com/StckMasterFlash/status/1935049659816214802 On track for key data readouts by September 2025, this expansion highlights both the growing momentum behind TTI-0102 and the strategic advantage of conducting trials in Europe’s increasingly efficient regulatory landscape for orphan diseases, over the US FDA. $MNPR $XENE
0 · Reply
wavess
wavess Jun. 17 at 6:54 PM
$TTIPF Today, Thiogenesis Therapeutics, a clinical-stage biotech, has announced the activation of its second clinical site in France for the ongoing Phase 2 trial of its lead candidate, TTI-0102, in patients with MELAS, marking a key expansion milestone for the multicenter European study: https://www.newsfilecorp.com/release/255687/Thiogenesis-Announces-Second-Site-Begins-Enrolling-in-Phase-2-MELAS-Clinical-Trial-and-Provides-Update The randomized, double-blind, placebo-controlled, multi-country and multi-center trial is active in Europe and marks a major milestone for the company, bringing a potential treatment to "one of the most prevalent and debilitating of the inherited mitochondrial diseases for which there are no approved drugs in the EU or the U.S." This update follows TTI receiving FDA clearance to launch a Phase 2a trial for TTI-0102 in Leigh Syndrome Spectrum with the Children's Hospital of Philadelphia—a rare, life-threatening mitochondrial disorder with no approved treatments. More info: https://x.com/StckMasterFlash/status/1932861013423984766
0 · Reply
newsfile_corp
newsfile_corp Jun. 17 at 1:01 PM
https://nfne.ws/255687 $TTIPF $TTI.TSXV #InvestmentBanking #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Investing
0 · Reply
wavess
wavess Jun. 13 at 4:58 PM
$TTIPF Marks a pivotal moment in affirming the scientific and clinical promise of its lead candidate, Thiogenesis Therapeutics received FDA clearance to launch a Phase 2a trial for TTI-0102 in Leigh Syndrome Spectrum—a rare, life-threatening mitochondrial disorder with no approved treatments: https://x.com/StckMasterFlash/status/1932861013423984766 This approval is a critical endorsement, especially given the early-stage nature of the asset and the disease's high unmet need; validating TTI's approach of targeting oxidative stress via intracellular cysteine and glutathione elevation and signalling confidence in the safety and potential efficacy of TTI-0102, which is additionally in clinical trials in Europe for MELAS.
0 · Reply
wavess
wavess Jun. 12 at 4:11 PM
$TTIPF Yesterday, Thiogenesis Therapeutics announced it has received FDA clearance to launch a Phase 2a trial for TTI-0102 in Leigh Syndrome Spectrum—a rare, life-threatening mitochondrial disorder with no approved treatments. Backed by leading experts at Children’s Hospital of Philadelphia, a leader in pediatric mitochondrial medicine, serving as the lead clinical site, and strong preclinical data, the study will assess TTI-0102’s potential to reduce oxidative stress and improve quality of life for patients. This milestone marks a major step toward addressing a critical unmet medical need and positions TTI for potential breakthrough therapy designation - in addition to TTI's current Phase 2 clinical trial in Europe for MELAS, another rare pediatric mitochondrial disease that currently has no approved treatment. Check out the full story here: https://x.com/StckMasterFlash/status/1932861013423984766
0 · Reply